# CervoMed to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/CRVO/cervomed-to-participate-in-upcoming-investor-conferences-59aadfc0
Ticker: CRVO
Company: CervoMed
Source: CervoMed
Published: 2026-03-05 12:30 EST
## Summary

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related...

## Article Body
CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will participate in the following investor conferences during the month of March:

Leerink Global Healthcare Conference Format: 1x1 Investor Meetings Date: Wednesday, March 11, 2026

38 th Annual ROTH Conference Format: Fireside Chat & 1x1 Investor Meetings Presentation Date: Monday, March 23, 2026 Presentation Time: 12:00 – 12:30 PM PT

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://ir.cervomed.com/news-events/events-and-presentations

About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in DLB patients who have a low likelihood of AD co-pathology, and the Company plans to initiate a global, pivotal Phase 3 trial in the same patient population in the second half of 2026, subject to available funding.

Contacts:

Media: Lisa Guiterman Biongage Communications lisa.guiterman@gmail.com 202-330-3431

Investor Relations: Argot Partners cervomed@argotpartners.com 212-600-1902
## Recent Company News
- 2026-04-22 11:30 EST — [CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies](https://biopharmsignal.com/news/CRVO/cervomed-announces-new-data-at-the-2026-aan-annual-meeting-that-demonstrated-nef-cd73de51) — Source: CervoMed
- 2026-04-07 11:30 EST — [CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting](https://biopharmsignal.com/news/CRVO/cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-pa-a8806faf) — Source: CervoMed
- 2026-03-19 11:30 EST — [CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology](https://biopharmsignal.com/news/CRVO/cervomed-announces-new-data-at-the-ad-pd-2026-scientific-conference-that-reinfor-c5e9beb0) — Source: CervoMed
- 2026-03-17 11:30 EST — [CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/CRVO/cervomed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provide-bb15de98) — Source: CervoMed
- 2026-03-12 11:00 EST — [CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference](https://biopharmsignal.com/news/CRVO/cervomed-announces-presentations-at-upcoming-ad-pd-2026-scientific-conference-fb00b88c) — Source: CervoMed
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)